Systems biology approach reveals genome to phenome correlation in type 2 diabetes
Genome-wide association studies (GWASs) have discovered association of several loci with Type 2 diabetes (T2D), a common complex disease characterized by impaired insulin secretion by pancreatic β cells and insulin signaling in target tissues. However, effect of genetic risk variants on continuous glycemic measures in nondiabetic subjects mainly elucidates perturbation of insulin secretion. Also, the disease associated genes do not clearly converge on functional categories consistent with the known aspects of T2D pathophysiology. We used a systems biology approach to unravel genome to phenome correlation in T2D. We first examined enrichment of pathways in genes identified in T2D GWASs at genome-wide or lower levels of significance. Genes at lower significance threshold showed enrichment of insulin secretion related pathway. Notably, physical and genetic interaction network of these genes showed robust enrichment of insulin signaling and other T2D pathophysiology related pathways including insulin secretion. The network also overrepresented genes reported to interact with insulin secretion and insulin action targeting antidiabetic drugs. The drug interacting genes themselves showed overrepresentation of insulin signaling and other T2D relevant pathways. Next, we generated genome-wide expression profiles of multiple insulin responsive tissues from nondiabetic and diabetic patients. Remarkably, the differentially expressed genes showed significant overlap with the network genes, with the intersection showing enrichment of insulin signaling and other pathways consistent with T2D pathophysiology. Literature search led our genomic, interactomic, transcriptomic and toxicogenomic evidence to converge on TGF-beta signaling, a pathway known to play a crucial role in pancreatic islets development and function, and insulin signaling. Cumulatively, we find that GWAS genes relate directly to insulin secretion and indirectly, through collaborating with other genes, to insulin resistance. This seems to support the epidemiological evidence that environmentally triggered insulin resistance interacts with genetically programmed β cell dysfunction to precipitate diabetes.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2013 |
---|---|
Erschienen: |
2013 |
Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
---|---|
Enthalten in: |
PloS one - 8(2013), 1 vom: 20., Seite e53522 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Jain, Priyanka [VerfasserIn] |
---|
Links: |
---|
Themen: |
Hypoglycemic Agents |
---|
Anmerkungen: |
Date Completed 02.07.2013 Date Revised 21.10.2021 published: Print-Electronic GEO: GSE29221, GSE29226, GSE29231 Citation Status MEDLINE |
---|
doi: |
10.1371/journal.pone.0053522 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM224092154 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM224092154 | ||
003 | DE-627 | ||
005 | 20231224062145.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231224s2013 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1371/journal.pone.0053522 |2 doi | |
028 | 5 | 2 | |a pubmed24n0747.xml |
035 | |a (DE-627)NLM224092154 | ||
035 | |a (NLM)23308243 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Jain, Priyanka |e verfasserin |4 aut | |
245 | 1 | 0 | |a Systems biology approach reveals genome to phenome correlation in type 2 diabetes |
264 | 1 | |c 2013 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 02.07.2013 | ||
500 | |a Date Revised 21.10.2021 | ||
500 | |a published: Print-Electronic | ||
500 | |a GEO: GSE29221, GSE29226, GSE29231 | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Genome-wide association studies (GWASs) have discovered association of several loci with Type 2 diabetes (T2D), a common complex disease characterized by impaired insulin secretion by pancreatic β cells and insulin signaling in target tissues. However, effect of genetic risk variants on continuous glycemic measures in nondiabetic subjects mainly elucidates perturbation of insulin secretion. Also, the disease associated genes do not clearly converge on functional categories consistent with the known aspects of T2D pathophysiology. We used a systems biology approach to unravel genome to phenome correlation in T2D. We first examined enrichment of pathways in genes identified in T2D GWASs at genome-wide or lower levels of significance. Genes at lower significance threshold showed enrichment of insulin secretion related pathway. Notably, physical and genetic interaction network of these genes showed robust enrichment of insulin signaling and other T2D pathophysiology related pathways including insulin secretion. The network also overrepresented genes reported to interact with insulin secretion and insulin action targeting antidiabetic drugs. The drug interacting genes themselves showed overrepresentation of insulin signaling and other T2D relevant pathways. Next, we generated genome-wide expression profiles of multiple insulin responsive tissues from nondiabetic and diabetic patients. Remarkably, the differentially expressed genes showed significant overlap with the network genes, with the intersection showing enrichment of insulin signaling and other pathways consistent with T2D pathophysiology. Literature search led our genomic, interactomic, transcriptomic and toxicogenomic evidence to converge on TGF-beta signaling, a pathway known to play a crucial role in pancreatic islets development and function, and insulin signaling. Cumulatively, we find that GWAS genes relate directly to insulin secretion and indirectly, through collaborating with other genes, to insulin resistance. This seems to support the epidemiological evidence that environmentally triggered insulin resistance interacts with genetically programmed β cell dysfunction to precipitate diabetes | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 7 | |a Hypoglycemic Agents |2 NLM | |
650 | 7 | |a Insulin |2 NLM | |
650 | 7 | |a Transforming Growth Factor beta |2 NLM | |
700 | 1 | |a Vig, Saurabh |e verfasserin |4 aut | |
700 | 1 | |a Datta, Malabika |e verfasserin |4 aut | |
700 | 1 | |a Jindel, Dinesh |e verfasserin |4 aut | |
700 | 1 | |a Mathur, Ashok Kumar |e verfasserin |4 aut | |
700 | 1 | |a Mathur, Sandeep Kumar |e verfasserin |4 aut | |
700 | 1 | |a Sharma, Abhay |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t PloS one |d 2006 |g 8(2013), 1 vom: 20., Seite e53522 |w (DE-627)NLM167327399 |x 1932-6203 |7 nnns |
773 | 1 | 8 | |g volume:8 |g year:2013 |g number:1 |g day:20 |g pages:e53522 |
856 | 4 | 0 | |u http://dx.doi.org/10.1371/journal.pone.0053522 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 8 |j 2013 |e 1 |b 20 |h e53522 |